What have we really learned from 'LIBERATE' trial?
LIBERATE trial reports that Tibolone use increases the risk of recurrence in breast cancer patients with vasomotor symptoms. However, there are some uncertainties and weak points in the study. Emerged questions are if interpretation of the results could be extrapolated to all breast cancer patients or there are specific subgroups that could use Tibolone without increasing relapse rate.